MAP2K7 and Ehlers-Danlos syndrome, musculocontractural type: Only the small proportion of BRAFV600E-mutated ATC (about 20%) can be effectively treated with a BRAF/MEK inhibitor combination of dabrafenib and trametinib (10,11), but for the other 70–80% of ATCs, no treatment options are approved after chemotherapy failure in most countries.